ArunA Bio is harnessing the natural abilities of neural exosomes to cross the blood brain barrier and enhance the body's anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders. ArunA Bio is also leveraging its proprietary exosomes and manufacturing platform to create synergistic therapies by enhancing exosomes with RNA, oligonucleotides, antibodies and small molecules.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/25/19 | $13,000,000 | Common Stock |
Eshelman Ventures | undisclosed |
